SciELO - Scientific Electronic Library Online

 
vol.35 número4Tratamiento farmacológico en la fibrosis pulmonar idiopática. Drogas modificadoras de enfermedad¿Cómo realizar el seguimiento de los pacientes con fibrosis pulmonar idiopática? índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google

Compartir


Revista chilena de enfermedades respiratorias

versión On-line ISSN 0717-7348

Resumen

UNDURRAGA P, ÁLVARO et al. Adjuvant therapies to antifibrotic therapy in IPF. Importance of multidisciplinary management. Rev. chil. enferm. respir. [online]. 2019, vol.35, n.4, pp.293-303. ISSN 0717-7348.  http://dx.doi.org/10.4067/S0717-73482019000400293.

Idiopathic pulmonary fibrosis (IPF) is characterized by reduced functional capacity, dyspnea and exercise-induced hypoxia, which decreases tolerance to exertion and limits the ability to perform daily activities. Comorbidities are frequent and their presence contribute to worsening quality of life and increased mortality. Therefore, in addition to antifibrotic therapies, patients with IPF benefit of a comprehensive approach to care that may include: screening, diagnosis and treatment of comorbidities, admission to research protocols, symptomatic management, palliative care, supplementary oxygen, pulmonary rehabilitation, education and support by a multidisciplinary team.

Palabras clave : Idiopathic Pulmonary Fibrosis; Comorbidity; Quality of Life; Palliative Care; Oxygen; Patient Care Team.

        · resumen en Español     · texto en Español     · Español ( pdf )